Trastuzumab-based combination treatment with chemotherapy are, however, effective in 60–70% of the HER2-overexpressing breast cancers [7], [9] and trastuzumab resistance often develops during the course of treatment [9], [10]. Here, ERBB2 is linked to breast carcinoma.